Overview
- The collaboration covers eight programmes, with four initially advanced using CSPC’s AI-driven peptide design and LiquidGel once‑monthly injectable platform.
- AstraZeneca secures exclusive rights outside China to SYH2082, a long‑acting GLP‑1/GIP agonist, and three preclinical weight‑management assets.
- CSPC will conduct development through Phase 1 before AstraZeneca takes over later-stage development and commercialisation outside China; CSPC retains rights in China, Taiwan, Hong Kong and Macau.
- Financial terms include a $1.2 billion upfront payment and up to $3.5 billion in development and regulatory milestones, plus additional commercialisation and sales milestones with tiered royalties.
- The transaction is expected to close in the second quarter of 2026 and expands AstraZeneca’s weight‑management portfolio alongside its separate plan to invest $15 billion in China through 2030.